MedTrace Logo

TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants

NCT02723201 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the relative bioavailability of solid oral formulations of TAK-020 in comparison with single dose of TAK-020 oral solution formulation and to evaluate the food effect and potentially the dose proportionality of the optimal oral solid formulation.

Conditions

  • Healthy

Interventions

DRUG

TAK-020 Captisol Oral Solution

TAK-020 solution.

DRUG

TAK-020 CCT

TAK-020 co-crystal tablet

DRUG

TAK-020 SDT

TAK-020 Solid dispersion tablet.

DRUG

TAK-020 IRT

TAK-020 immediate release tablet.

DRUG

TAK-020 CCT

TAK-020 co-crystal tablet.

DRUG

TAK-020 Solid Formulation

TAK-020 solid formulation

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-28
Primary Completion
2016-08-05
Completion
2016-08-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723201 on ClinicalTrials.gov